# Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

> **NCT06197438** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Levo-Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06197438
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-04-11
- **Final completion:** 2025-04-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06197438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06197438, "Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06197438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*